Traduction de «also cooperating with an » (Néerlandais → Français) :

NPC is also cooperating with an investigation by the EDPA regarding potential off-label marketing and promotion as well as payments made to healthcare providers in connection with five other products, i.e.
NPC coopère également à une enquête de l’EDPA sur des accusations de commercialisation et de promotion ainsi que de paiements à des prestataires de soins de santé portant sur des indications pour lesquelles cinq autres produits n’ont pas été autorisés. Il s’agit de Diovan, Exforge, Sandostatine, Tekturna et Zelnorm.

Considerable attention was focused in 2007 on increased cooperation on the part of the FAMHP with the ethics committees, with the following results: ●● An interactive website with a web application that makes possible the “simple” management of communication actions between the different ethics committees, the FAMHP, the sponsors and researchers, and also monitors the different stages in the evaluation of each application by the ethics committees ●● Systematic consultation for the more complex scientific applications ●● Further optimisation of the functioning of
Considerable attention was focused in 2007 on increased cooperation on the part of the FAMHP with the ethics committees, with the following results: ●● An interactive website with a web application that makes possible the “simple” management of communication actions between the different ethics committees, the FAMHP, the sponsors and researchers, and also monitors the different stages in the evaluation of each application by the ethics committees ●● Systematic consultation for the more complex scientific applications ●● Further optimisation of the functioning of

Novartis is also cooperating with an inquiry by the EDPA regarding similar allegations of potential off-label marketing and promotion and payments to healthcare providers in connection with five other products: Diovan, Exforge, Sandostatin, Tekturna and Zelnorm.
Novartis coopère également avec l’EPDA dans le cadre d’une enquête concernant des accusations similaires en relation avec cinq autres produits: Diovan, Exforge, Sandostatine, Tekturna et Zelnorm.

NPC has also been cooperating with an investigation by the EDPA regarding potential off-label marketing and promotion as well as payments made to healthcare providers in connection with five other products, i.e. Diovan, Exforge, Sandostatin, Tekturna and Zelnorm (Five Products).
NPC a également coopéré à une enquête menée par l’EDPA au sujet d’accusations de promotion pour des indications pour lesquelles des produits n’ont pas été autorisés, et de paiements à des prestataires de soins de santé en lien avec cinq autres produits: Diovan, Exforge, Sandostatine, Tekturna et Zelnorm.

Direct cooperation with dossier administrators who monitor the central procedure (CP) is also required.
Direct cooperation with dossier administrators who monitor the central procedure (CP) is also required.

Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office DGO - SCM guidance committee (with APB and OPHACO) e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees ICVV – CICSA Influenza (in cooperation with external partners) Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Inter DG drugs (with FPS Public Health) Mdeon board of management Potassium iodide tablets campaign (with FPS Interior Affairs) Provincial medical commissions (with FPS Public Health) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI)
Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office DGO - SCM guidance committee (with APB and OPHACO) e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees ICVV – CICSA Influenza (in cooperation with external partners) Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Inter DG drugs (with FPS Public Health) Mdeon board of management Potassium iodide tablets campaign (with FPS Interior Affairs) Provincial medical commissions (with FPS Public Health) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI)

Enhancing the organisation’s image and improving online communication In 2007 an intranet was launched in cooperation with the Communication & Scientific Support service and there are plans to develop a brandnew website with the BUM department that will group existing sites and optimise internal and external communication.
Enhancing the organisation’s image and improving online communication In 2007 an intranet was launched in cooperation with the Communication & Scientific Support service and there are plans to develop a brandnew website with the BUM department that will group existing sites and optimise internal and external communication.

Interdepartmental committee of experts on blood, organs, ICVV – CICSA cells, tissues and embryos (with FPS Public Health, KCE, RIZIV Influenza (in cooperation with external partners)
Interdepartmental committee of experts on blood, organs, ICVV – CICSA cells, tissues and embryos (with FPS Public Health, KCE, RIZIV Influenza (in cooperation with external partners)

Efficient cooperation between the departments within a pillar and with relevant departments in the other pillars must be ensured.
Efficient cooperation between the departments within a pillar and with relevant departments in the other pillars must be ensured.

The evolution of the EARLY PHASE DEVELOPMENT spearhead requires an ad hoc approach with cooperation between various experts rather than pursuing “continuous activity”.
The evolution of the EARLY PHASE DEVELOPMENT spearhead requires an ad hoc approach with cooperation between various experts rather than pursuing “continuous activity”.